0001140361-21-041286.txt : 20211210
0001140361-21-041286.hdr.sgml : 20211210
20211210210052
ACCESSION NUMBER: 0001140361-21-041286
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211208
FILED AS OF DATE: 20211210
DATE AS OF CHANGE: 20211210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cherington Charles
CENTRAL INDEX KEY: 0001448698
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11460
FILM NUMBER: 211486778
MAIL ADDRESS:
STREET 1: ONE BOW STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc.
CENTRAL INDEX KEY: 0000748592
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 311103425
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
BUSINESS PHONE: (212) 582-1199
MAIL ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
FORMER COMPANY:
FORMER CONFORMED NAME: NTN BUZZTIME INC
DATE OF NAME CHANGE: 20051230
FORMER COMPANY:
FORMER CONFORMED NAME: NTN COMMUNICATIONS INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: ALROY INDUSTRIES INC
DATE OF NAME CHANGE: 19850411
4
1
form4.xml
FORM 4
X0306
4
2021-12-08
0000748592
Brooklyn ImmunoTherapeutics, Inc.
BTX
0001448698
Cherington Charles
C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
140 58TH STREET, BUILDING A, SUITE 2100
BROOKLYN
NY
11220
true
Common Stock
2021-06-01
5
J
0
92
0
A
5894193
D
Stock Option
5.94
2021-12-08
4
A
0
67000
0
A
2031-12-07
Common Stock
67000
67000
D
Represents a stock dividend declared on shares of the Issuer's Series A Preferred Stock.
A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date.
/s/ Mark L. Johnson, Attorney-in-Fact for Charles Cherington
2021-12-10